NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report published on Tuesday morning,Benzinga reports. They currently have a $34.00 target price on the stock.

NRXP has been the topic of a number of other reports. Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a report on Wednesday, September 10th. Ascendiant Capital Markets lifted their price target on NRx Pharmaceuticals from $46.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of NRx Pharmaceuticals in a report on Thursday, October 16th. Finally, BTIG Research restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Monday, August 25th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, NRx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $34.75.

NRx Pharmaceuticals Price Performance

NRXP stock opened at $2.27 on Tuesday. The company’s 50-day moving average is $2.85 and its 200-day moving average is $2.89. The stock has a market capitalization of $63.79 million, a PE ratio of -0.97 and a beta of 1.91. NRx Pharmaceuticals has a 1 year low of $1.15 and a 1 year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $6.83 million. On average, analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in NRXP. Anson Funds Management LP raised its stake in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock valued at $2,417,000 after buying an additional 993,401 shares during the period. Vanguard Group Inc. raised its position in shares of NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. AdvisorShares Investments LLC raised its position in shares of NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. Geode Capital Management LLC lifted its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.